AGP Picks
View all

The best science and technology news from Rhode Island

Provided by AGP

Rhode Island Technology Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Rhode Island Technology Weekly.

Press releases published on April 27, 2026

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
Allot to Release First Quarter 2026 Results and Host Conference Call on May 12, 2026
Aeluma Appoints Willy Rachmady Vice President of Strategic Partnerships and Ecosystem
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Recognized for Best Use of Tech in HR, Vetty Wins Bronze Stevie® in 2026 American Business Awards®
Palomino Laboratories Inc. Closes $15 Million at $4/share
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Sagimet Biosciences Provides Strategic and Corporate Updates
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator 

Share us

on your social networks:

Sign up for:

Rhode Island Technology Weekly

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.